The effect of linagliptin on renal progression in type-2 diabetes mellitus patients with chronic kidney disease: A prospective randomized controlled study
| Autor: | Berkan Akcakaya, Ali Ihsan Gunal, Ali Ihsan Yagoglu, Selahattin Erdem, Oguzhan Sitki Dizdar |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment 030232 urology & nephrology Urology Linagliptin 030209 endocrinology & metabolism lcsh:RC870-923 law.invention Evolución renal Diabetic nephropathy 03 medical and health sciences Sex Factors 0302 clinical medicine Diabetes mellitus Randomized controlled trial law Insulina medicine Humans Insulin Prospective Studies Renal Insufficiency Chronic Aged Dipeptidyl-Peptidase IV Inhibitors Proteinuria business.industry Type 2 Diabetes Mellitus medicine.disease Linagliptina lcsh:Diseases of the genitourinary system. Urology Diabetes Mellitus Type 2 Nephrology Disease Progression Regression Analysis Control glucémico Female medicine.symptom business Glomerular Filtration Rate Kidney disease medicine.drug |
| Zdroj: | Nefrología (English Edition), Vol 40, Iss 6, Pp 664-671 (2020) Nefrología, Vol 40, Iss 6, Pp 664-671 (2020) |
| ISSN: | 2013-2514 |
| Popis: | Background: Linagliptin does not require dose adjustment in diabetes mellitus patients with chronic kidney disease (CKD). But, renal effects of linagliptin are not clear. Our aim was to examine the effect of linagliptin on renal disease progression in only insulin dependent type 2 diabetes mellitus (DM) patients with CKD. Methods: Stage 3–4 CKD patients were randomized into 2 groups in this prospective randomized controlled study. In the first group, linagliptin 5 mg was added in addition to the background insulin therapy. In the second group, patients continued their insulin therapy. Patients were followed up at 3-month intervals for one year. Results: The study population consisted of 164 patients (90 patients in linagliptin group, 74 patients in other group) with a mean age of 67.5 ± 8.8 years. eGFR significantly increased in linagliptin group (p = 0.033), but decreased in other group (p = 0.003). No significant change was observed in total insulin dose in linagliptin group (p = 0.111), but in other group, total insulin dose significantly increased (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|